The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development
An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, su...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/104105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555923452723200 |
|---|---|
| author | Noah S. Philip Linda L. Carpenter Audrey R. Tyrka Lawrence H. Price |
| author_facet | Noah S. Philip Linda L. Carpenter Audrey R. Tyrka Lawrence H. Price |
| author_sort | Noah S. Philip |
| collection | DOAJ |
| description | An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, such as stress and inflammation. The two classes of drugs that target nAChRs can be broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their effects via antagonism at α4β2 nAChRs, and strong preclinical data support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development. |
| format | Article |
| id | doaj-art-67a98682da06467e82bce17121dfd0d0 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-67a98682da06467e82bce17121dfd0d02025-02-03T05:46:44ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/104105104105The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug DevelopmentNoah S. Philip0Linda L. Carpenter1Audrey R. Tyrka2Lawrence H. Price3Mood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USAMood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USAMood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USAMood Disorders Research Program, Butler Hospital and Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02906, USAAn important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, such as stress and inflammation. The two classes of drugs that target nAChRs can be broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their effects via antagonism at α4β2 nAChRs, and strong preclinical data support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development.http://dx.doi.org/10.1100/2012/104105 |
| spellingShingle | Noah S. Philip Linda L. Carpenter Audrey R. Tyrka Lawrence H. Price The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development The Scientific World Journal |
| title | The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development |
| title_full | The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development |
| title_fullStr | The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development |
| title_full_unstemmed | The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development |
| title_short | The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development |
| title_sort | nicotinic acetylcholine receptor as a target for antidepressant drug development |
| url | http://dx.doi.org/10.1100/2012/104105 |
| work_keys_str_mv | AT noahsphilip thenicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT lindalcarpenter thenicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT audreyrtyrka thenicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT lawrencehprice thenicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT noahsphilip nicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT lindalcarpenter nicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT audreyrtyrka nicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment AT lawrencehprice nicotinicacetylcholinereceptorasatargetforantidepressantdrugdevelopment |